文献速递心境障碍焦虑、强迫与应激相关障碍

α5-GABAA受体正负变构调节剂治疗情感障碍的临床前比较

A Comparison of Positive and Negative Allosteric Modulators of α5-Containing GABAA Receptors in the Treatment of Affective Disease.
PubMed 文献 · Biol Psychiatry · 2025-11-08

本文综述了靶向α5亚单位GABAA受体的正变构调节剂(PAM)与负变构调节剂(NAM)在情感障碍临床前模型中的文献。α5-PAM在抗焦虑范式中最有效并普遍减少绝望样行为;α5-NAM则显著逆转慢性应激后的奖赏寻求缺陷、有效缓解快感缺失,但 largely 无抗焦虑作用。两类化合物均显示促认知效应。

要点

  • α5-PAM在抗焦虑行为范式中效果最强,并普遍减少绝望样行为。
  • α5-NAM显著逆转慢性应激后的奖赏寻求缺陷,有效缓解快感缺失。
  • α5-NAM具有抗绝望样作用但基本无抗焦虑效应;两类均有促认知效应。

核心结论

  • α5-Preferring GABA-PAMs在抗焦虑范式中最有效并普遍减少绝望样行为,而α5-preferring GABA-NAMs显著逆转慢性应激后的奖赏寻求缺陷、有效缓解快感缺失。
  • α5-preferring GABA-NAMs虽有抗绝望样作用但基本无抗焦虑效应,两类化合物均显示促认知效应。

研究设计与样本

  • 本综述汇总α5偏好性GABA-PAMs与GABA-NAMs在情感疾病临床前模型中的现有文献。
  • 将啮齿类个体行为模型效应归类为奖赏行为、绝望样行为、焦虑样行为和认知行为。

主要发现

  • α5-preferring GABA-PAMs在抗焦虑行为范式中临床前疗效最大,并普遍减少绝望样行为。
  • α5-preferring GABA-NAMs在慢性应激后显著逆转奖赏寻求行为缺陷,有效缓解快感缺失。
  • α5-preferring GABA-NAMs有抗绝望样作用但 largely 无抗焦虑作用;两类均有促认知效应。
  • α5-preferring GABA-PAMs在GABA能功能低下的临床前模型中显示额外疗效。

临床怎么用

  • 针对快感缺失为主的抑郁症状,α5-preferring GABA-NAMs是值得关注的转化候选。
  • 针对焦虑症状突出者,α5-preferring GABA-PAMs的临床前证据更强。
  • 两类化合物均有促认知效应,提示对抑郁相关认知损害可能有潜在价值。

局限性

  • 证据来自临床前文献综述,尚不能直接推导临床疗效。
  • MDD是人类特有异质性障碍,啮齿类行为模型分类仅部分对应临床症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) is a common psychiatric disease that significantly impairs quality of life and productivity. Standard monoamine-based therapies are marred by poor efficacy. Disruptions in the balance of glutamate- and GABA (gamma-aminobutyric acid)-mediated neurotransmission in regions associated with reward, emotion, and cognitive processing likely underpin the neurobiology of depression. Subunit-preferring compounds may positively (GABA-positive allosteric modulators [PAMs]) or negatively (GABA-negative allosteric modulators [NAMs]) modulate the ability of GABA to activate inhibitory GABAA receptors containing α5 subunits, predominantly expressed in these corticolimbic structures. Despite opposing mechanistic actions, both classes of compounds have recently demonstrated promise in preclinical models of depression-like symptoms. This review therefore aims to bridge the gap by summarizing the current preclinical literature of α5-preferring GABA-PAMs and GABA-NAMs in models of affective disease. As MDD is a uniquely human disorder with diverse symptoms, effects in individual rodent behavioral models are further classified into discrete categories of reward behavior, despair-like behavior, anxiety-like behavior, and cognitive behavior. From the literature, we identified a clear trend: α5-preferring GABA-PAMs have greatest preclinical efficacy in anxiolytic behavioral paradigms and generally reduce despair-like behavior. In contrast, α5-preferring GABA-NAMs dramatically reverse reward-seeking behavioral deficits following chronic stress, thus effectively relieving anhedonia-a primary symptom of MDD. However, while α5-preferring GABA-NAMs demonstrate anti-despair-like actions, they are largely not anxiolytic. Both classes demonstrate nootropic effects; however, α5-preferring GABA-PAMs have shown additional efficacy in preclinical models characterized by GABAergic hypofunction. Modulating α5-mediated GABAergic transmission has broad potential to treat psychiatric illness, and compounds that demonstrate efficacy across diverse preclinical behavioral domains represent promising translational candidates.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Troppoli TA, Thompson SM. A Comparison of Positive and Negative Allosteric Modulators of α5-Containing GABAA Receptors in the Treatment of Affective Disease. Biol Psychiatry. 2025. PMID: 41213393. doi:10.1016/j.biopsych.2025.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。